Brokerages forecast that Translate Bio Inc (NASDAQ:TBIO) will post earnings per share (EPS) of ($0.46) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Translate Bio’s earnings. Translate Bio posted earnings of ($2.94) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 84.4%. The firm is expected to report its next earnings results on Thursday, August 8th.
On average, analysts expect that Translate Bio will report full year earnings of ($1.30) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will report earnings of ($2.00) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Translate Bio.
Translate Bio (NASDAQ:TBIO) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.04). The company had revenue of $1.47 million during the quarter.
NASDAQ TBIO opened at $10.03 on Wednesday. Translate Bio has a 1-year low of $4.81 and a 1-year high of $16.60. The company has a market capitalization of $510.56 million and a P/E ratio of -2.76. The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 1.34.
A number of institutional investors have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board increased its position in Translate Bio by 28.7% during the first quarter. State of Wisconsin Investment Board now owns 13,000 shares of the company’s stock worth $132,000 after buying an additional 2,900 shares in the last quarter. Barclays PLC increased its position in Translate Bio by 82.8% during the fourth quarter. Barclays PLC now owns 6,710 shares of the company’s stock worth $50,000 after buying an additional 3,039 shares in the last quarter. JPMorgan Chase & Co. increased its position in Translate Bio by 186.4% during the first quarter. JPMorgan Chase & Co. now owns 7,175 shares of the company’s stock worth $73,000 after buying an additional 4,670 shares in the last quarter. Aevitas Wealth Management Inc. purchased a new position in Translate Bio during the first quarter worth $58,000. Finally, BNP Paribas Arbitrage SA purchased a new position in Translate Bio during the first quarter worth $63,000. 57.90% of the stock is owned by institutional investors.
About Translate Bio
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Recommended Story: How Investors Can Profit from Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.